Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Aspirin Low Dose (Pharmacy Action) TM
Active ingredients: aspirin
What it is used for
For the treatment of patients with known cardiovascular or cerebrovascular disease an antiplatelet agent for prophylaxis against acute myocardial infarction, unstable angina, transient ischaemic attack and cerebrovascular accident (stroke)
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Oral
- Store below 30 degrees Celsius
- Lifetime is 36 Months.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Orange coloured circular, biconvex coated tablet having Heart shape embossed on one side and plain on other side.
Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
The packs below are available from a pharmacy without prescription. It is
- 120, pack
- 150, pack
- 168, pack
- 180, pack
We are unable to tell you if you need a prescription for these medicines. You can ask your pharmacist. This medicine is
- 10, pack
- 14, pack
- 28, pack
- 30, pack
- 60, pack
- 84, pack
- 90, pack
Over 65?
This medicine contains the active ingredients:
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
Pregnant or planning a pregnancy?
For the active ingredient aspirin
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Need more information?
These trusted information partners have more on this topic.
Top results
APO-Dipyridamole/Aspirin Modified release capsules - myDr.com.au
APO-Dipyridamole/Aspirin Modified release capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Clopidogrel Winthrop Plus Aspirin Tablets - myDr.com.au
Clopidogrel Winthrop Plus Aspirin Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Clopidogrel/Aspirin Sandoz 75/100 Tablets - myDr.com.au
Clopidogrel/Aspirin Sandoz 75/100 Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Diasp SR Sustained release capsules - myDr.com.au
Diasp SR Sustained release capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Asasantin SR Sustained release capsules - myDr.com.au
Asasantin SR Sustained release capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Astrix 100 Capsules - myDr.com.au
Astrix 100 Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
CoPlavix Tablets - myDr.com.au
CoPlavix Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
DuoPlidogrel Tablets - myDr.com.au
DuoPlidogrel Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Prescribing for people with acute rheumatic fever | Issue 2 | Volume 40 | Australian Prescriber | Australian Prescriber
Check out the recent changes in Australian recommendations for antibiotic use, aspirin dose and prevention of endocarditis.
Read more on Australian Prescriber website
Returning unwanted medicinesto pharmacies: prescribing toreduce waste | Australian Prescriber
The Return Unwanted Medicines Project is a free and safe way for consumers to dispose of unwanted medicines at...
Read more on Australian Prescriber website
Top results
There is no evidence that aspirin improves the symptoms of vascular dementia | Cochrane
Low-dose aspirin can improve the prognosis of heart disease and stroke, possibly by reducing clot formation within the blood vessels and helping to maintain or improve blood flow to the heart and brain. Many doctors assume that aspirin will also provide some benefit for people with vascular dementia.
Read more on Cochrane (Australasian Centre) website
Antiplatelet agents for preventing pre-eclampsia and its complications | Cochrane
Pre-eclampsia is a condition in pregnancy involving high blood pressure and protein in the urine. It can lead to serious complications. As it affects blood clotting, antiplatelets (drugs like aspirin which can prevent blood clots) are used to prevent pre-eclampsia. The review of 59 trials, involving 37,560 women, found low doses of aspirin reduced the risk of pre-eclampsia by about a sixth (17%), with a similar lowering in the risk of the baby dying (14%) and a small lowering in the risk of being born too early (8%). Doses up to 75 mg appear to be safe. Higher doses might be better, but adverse effects may also increase.
Read more on Cochrane (Australasian Centre) website
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease | Cochrane
Low-dose aspirin as antiplatelet therapy is still the drug of choice for preventing cardiovascular events, but the protection aspirin gives to people at high risk of cardiovascular events is only relatively modest. This review of 28,165 people in two trials where clopidogrel was given in addition to antiplatelet treatment found that in patients with acute coronary syndromes the benefit - a reduction in cardiovascular events - outweighs the harm of major bleeding. However, clopidogrel plus aspirin has no clear positive risk-benefit profile in people at high risk of cardiovascular events (multiple atherothrombotic risk factors) or in people with established cardiovascular disease (known coronary disease, ischemic cerebrovascular disease or peripheral arterial disease) but not presenting with an acute coronary syndrome, and the combination should not be prescribed routinely to prevent cardiovascular disease.
Read more on Cochrane (Australasian Centre) website
Antiplatelet agents and anticoagulants for hypertension | Cochrane
Daily aspirin reduces the incidence of heart attacks to a small degree, but increases the incidence of major bleeding events to a similar degree in patients treated for high blood pressure who have not had a prior stroke or heart attack. In patients with high blood pressure who have had a stroke or heart attack, the benefits of daily low-dose aspirin outweigh the harms. There is no evidence of benefit for antithrombotic therapy with warfarin alone or in combination with aspirin in patients with high blood pressure. The benefits and harms of the newer drugs glycoprotein IIb/IIIa inhibitors, clopidogrel, prasugrel, ticagrelor and oral antithrombotic agents such as dabigatran and rivaroxaban for patients with high blood pressure have not been studied in clinical trials.
Read more on Cochrane (Australasian Centre) website
Anticoagulants versus antiplatelet agents for acute ischaemic stroke | Cochrane
Treatment with anticoagulants offers no net advantages over antiplatelet agents in patients with acute ischaemic stroke. Ischaemic stroke is caused by a blood-clot blocking the blood supply to an area of the brain. Blood-thinning drugs, such as anticoagulants and antiplatelet agents, can potentially prevent arteries from being blocked, or prevent them re-blocking. They can also prevent clots forming in the deep veins in the leg, which can break off and travel to the lungs. However, such drugs can also cause bleeding complications, which might offset any benefits. Antiplatelet agents (mainly aspirin) are associated with long-term benefits and have become standard treatment for acute ischaemic stroke. This review aimed to test whether any anticoagulant regimen offers net advantages over antiplatelet agents, overall, or in specific categories of patients. There was no evidence that anticoagulants are superior to antiplatelet agents (in fact, anticoagulants caused a small increase in the number of deaths at long-term follow-up). However, the combination of low-dose anticoagulant and aspirin seemed to offer benefits over aspirin alone, and the combination should be investigated further.
Read more on Cochrane (Australasian Centre) website
Non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people taking methotrexate for inflammatory arthritis | Cochrane
Non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people taking methotrexate for inflammatory arthritis
Read more on Cochrane (Australasian Centre) website
Antiplatelet drugs for preventing arterial and venous thrombotic events in patients with polycythaemia vera or essential thrombocythaemia | Cochrane
Antiplatelet drugs for preventing arterial and venous thrombotic events in patients with polycythaemia vera or essential thrombocythaemia
Read more on Cochrane (Australasian Centre) website
Medical adjuvant treatment to increase the patency of arteriovenous fistulae and grafts used for renal dialysis | Cochrane
Read more on Cochrane (Australasian Centre) website
Corticosteroids versus placebo and NSAIDs for rheumatoid arthritis | Cochrane
Short-term low-dose corticosteroids compared with placebo and nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis
Read more on Cochrane (Australasian Centre) website
The effectiveness of low-dose corticosteroids in the treatment of rheumatoid arthritis disease activity over the moderate term | Cochrane
The effectiveness of low-dose corticosteroids in the treatment of rheumatoid arthritis disease activity over the moderate term
Read more on Cochrane (Australasian Centre) website
